Endocrinology Advisor

AHA Scientific Statement Links Mitochondrial Genetic Variants to CVD

The AHA recommended whole exome or whole genome sequencing as first-line diagnostic tools for mitochondrial diseases.

NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS ...

NRG5051 is a first-in-class, orally bioavailable and CNS-penetrant next-generation inhibitor of the mitochondrial permeability transition pore (mPTP), acting through a novel undisclosed ...

Tisento Therapeutics Completes Enrollment in PRIZM, a Global Phase 2b Study of Zagociguat for the Treatment of MELAS

Tisento Therapeutics today announced that the global Phase 2b PRIZM study is fully enrolled. PRIZM is evaluating zagociguat – a once-daily, oral investigational medicine – as a treatment for the rare ...
New Atlas

First proof brain’s powerhouses drive – and can reverse – dementia symptoms

Just a few days after scientists announced we're at a pivotal tipping point in Alzheimer's disease research, a team has made a huge breakthrough, proving for the first time how mitochondrial ...
TipRanks on MSN

Thiogenesis to showcase mitochondrial disease clinical progress at UMDF webinar

Thiogenesis Therapeutics Corp ( ($TSE:TTI) ) just unveiled an update. Thiogenesis Therapeutics announced that CEO Patrice Rioux will present ...
GEN

Mitochondrial Disease Milestone: Eight Babies Born Free of Disease via Pronuclear Transfer

Despite being renowned as the “powerhouse of the cell,” mitochondria can also be a source of heartache for those living with mitochondrial disease—especially when planning to have children. Because ...